Sir,

Methotrexate (MTX), a dihydrofolate reductase inhibitor and a first line drug for medical management of ectopic pregnancy, has an overall success rate of 88.1% with single-dose protocol. Approximately 10%--30% patients have mild self-limiting adverse effects, whereas very few cases of severe unexpected idiosyncratic reactions including nephrotoxicity, neurotoxicity, interstitial pneumonitis, alopecia dermatitis and myelosuppression may arise.\[[@ref1]\]

A 38-year-old female who came with left adnexal ectopic pregnancy was managed with injection (inj.) MTX 80 mg intramuscularly after ruling out its contraindications. After 6--8 h, patient became restless with difficulty in breathing, with SpO2 of 88% on room air, and had epigastric pain with 3--4 episodes of vomiting. On arrival in ICU, she had fever (100°F), tachycardia (hear rate 110/min), tachypnoea (respiratory rate 32 breath/min) along with basal crepitation in chest. Chest X-ray showed bilateral basal and mediastinal infiltrates \[[Figure 1](#F1){ref-type="fig"}\]. Arterial blood gas analysis revealed mild hypoxaemia with respiratory alkalosis. Oxygen supplementation, inj. ondansetron, inj. pheniramine maleate and inj. hydrocortisone 100 mg were given intravenously (IV) considering it a drug reaction. Empirically, inj. leucovorin 20 mg IV every 6 h was started. Due to lack of facility, serum MTX levels could not be done. Patient received generous IV fluids to maintain hydration, was given antibiotics and inj. Sodium bicarbonate to maintain urinary pH above 7, as on analysis it was found to be 6.

![X-ray showing bilateral infiltrates](IJA-63-870-g001){#F1}

The next day, patient developed icterus, yellow discolouration of urine and melaena along with elevated hepatic transaminases levels. Petechiae appeared over the lower limbs, neck and chest. Sepsis, disseminated intravascular coagulopathy, viral hepatitis and viral haemorrhagic fever were ruled out. Dermatology opinion suggested maculopapular rash probably due to drug toxicity or liver enzyme derangement \[[Figure 2](#F2){ref-type="fig"}\]. Later that day, she developed anasarca and urine output started decreasing along with deteriorating kidney function test (KFT) \[[Table 1](#T1){ref-type="table"}\]. Echocardiography was normal. As the patient became anuric, intermittent haemodialysis was started. On day 3, platelet count fell to 19,000 with INR 2.06 \[[Table 1](#T1){ref-type="table"}\]. On day 4, beta HCG dropped to 776, oxygen support tapered and patient received multiple transfusions (2 units packed red blood cells, 11 units fresh frozen plasma, 9 units random donor platelets). As all the three-cell lineage showed continuous fall despite multiple transfusions by day 6 too, inj. Filgrastim 5 μg/kg/day IV and inj. fluconazole 400 mg IV were given. Haemodialysis continued on daily basis. By day 7, beta HCG dropped to 227 and day 8 onwards, patient\'s platelet count and haemoglobin started improving. Patient continued to undergo maintenance haemodialysis thrice weekly for another week after which the KFT started improving. Finally, dialysis was tapered to twice weekly and patient was shifted to ward.

![Showing maculopapular rash on extremities](IJA-63-870-g002){#F2}

###### 

Table showing biochemical parameters during ICU stay

                                  Pre MTX   Day 1   Day 2   Day 3   Day 4   Day 5     Day 6     Day 7   Day 8    Day 10   Day 12   Day14
  ------------------------------- --------- ------- ------- ------- ------- --------- --------- ------- -------- -------- -------- --------
  Hb (gm/dl)                      13.4      10.9    13.5    10.1    10.3    9         6.0       6.3     7        7.6      8.4      8.6
  TLC (per cubic mm)              6580      6960    7200    12200   9400    5400      2650      3500    5830     6600     6100     7000
  Platelet count (per cubic mm)   2.32L     2.3L    2.02L   1.01L   48K     25K       15K       20K     20K      24K      44K      62K
  Haematocrit (%)                 37        36      36.6    29.8    27      27        18.6      19.2    20.8     22.8     25.6     18
  Total serum bilirubin (mg/dL)   0.4       0.4     3.8     3.9             8.2       6.8       5.4     3.2      1.7      1.6      1.42
  Direct bilirubin (mg/dL)                          2       3               4.8       4.3       3.2     1.6      0.6      0.6      0.5
  S. ALT (IU/L)                   18        16      38      434     700     225       198       122     48                57       54
  S. AST (IU/L)                   15        13      135     138             764       687       345     48                40       42
  S. ALP (IU/L)                   56                63              67      84        65        55      61                         71
  Blood urea (mg/dL)              32        75      36      103     126     125       121       175     167      159      128      95
  Serum creatinine (mg/dL)        0.7       0.7     1.7     3.9     4.6     4.6       4.8       5       4.7      4.6      4        3.2
  Serum sodium (mmol/L)           137       136     130     138     138     140       128       132                       140      142
  Serum potassium (mmol/L)        3.9       3.7     3.6     4       4.6     3.8       3.6       3.8                       4.1      3.8
  β- HCG (mlU/mL)                 1998                              776                         227                                
  INR                                                       1.417   2.917   2.5                 2.6              2.2               1.15
  APTT                                                                      \>3 min   \>2 min           98 sec                     32 sec
  D-dimer                                                                   \>5000                                                 4245

ICU: Intensive Care Unit, Hb: Haemoglobin, TLC: Total leucocyte count, DLC: Differential leucocyte count, L: 105, K: 103, S. ALT: Serum alanine aminotranferase, S. ALT: S. serum aspartate aminotransferase, S. ALP: Serum alkaline phosphatase, HCG: Human chorionic gonadotropin, INR: International normalised ratio, APTT: Activated partial thromboplastin time

Patient presented with signs of stomatitis, melena and petechiae in the beginning as MTX acts on sites with rapid cell turnover. As MTX crystallises in tubules, it decreases tubular secretion and increases likelihood of toxicity, more so in acidic urine.\[[@ref2]\] As 90% of IV MTX is excreted via renal route, its accumulation leads to myelosuppression and pancytopenia. Patients with already deranged KFT have 55% incidence of myelosuppression as against only 3% with normal KFT. Moreover, occurrence of myelosuppression after single low dose has hardly been reported.

Serious pancytopenia has been reported in around 1.4% of the cases. One reported case of ectopic pregnancy that had developed severe stomatitis, myelosuppression and pancytopenia and required one week of ICU treatment.\[[@ref3]\] Severe multiorgan involvement, though rare, can occur even with single dose, in patients with prior renal insufficiency. Extremes of age, malnutrition, folate deficiency and blood dyscrasias are among few other risk factors. Single-dose MTX toxicity in previously healthy females is a rare occurrence. Till date, only a single case of multiorgan involvement with early involvement of lungs has been reported in which pneumonitis developed on day 4 and multiorgan failure was noticed by a week. The probable reason for such fast involvement of organs was uncontrolled cytokine production following exaggerated cell-mediated reaction.\[[@ref4]\] Our patient had an unprecedented fulminant course, with a single day history of respiratory involvement and multiorgan involvement within two days. However high index of vigilance and aggressive ICU management prevented the disastrous consequences.

The standard-of-care regimen includes leucovorin along with continuous urinary alkalinisation (with sodium bicarbonate) and rigorous hydration. G-CSF, blood products and haemodialysis are other supportive measures.\[[@ref5][@ref6]\] Leucovorin, a rescue agent, exerts its effects via competitive cellular uptake though it does not sufficiently reduce MTX toxic levels. Glucarpidase, a carboxypeptidase, is needed in 2%--10% patients where nephrotoxicity may not reverse in normal pretreatment kidney.\[[@ref7]\] Although FDA approved for reversing MTX toxicity in patients with delayed MTX clearance, it is unavailable in India.\[[@ref8]\] Thymidine, rescues cells from the cytotoxic effects of MTX but its use is under investigation.
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